Quick navigation menu :

  1. Go to content
  2. Go to the main sections menu
  3. Go to the search engine
  4. Go to the help menu
  5. Go to the modules
  6. Go to the shortcuts list

Help menu :

  1. Sanofi Worldwide |
     
  2. Global Business Websites |
     
  3. Contact Us |
  4. Sitemap |
  5. Help
  1. Font size

    Reduce Increase  
 
 

Our Products

Contact Us

Sanofi-aventis Pakistan Limited

Registered Office

Plot 23, Sector 22
Korangi Industrial Area
Karachi-74900

Postal Address

P.O. Box 4962
Karachi-74000

Tel: 0800-70707

Content :

Tritace® (ramipril)

Tritace®

Tritace® Tablet 2.5 mg 1x28
Tritace® Tablet 5 mg 1x28
Tritace® 10 mg Tablets

Cardiovascular diseases are still the leading cause of death in industrialized countries

In these countries, atherosclerosis -the result of thickening and hardening of the arterial wall- is far and away the most common form of cardiovascular disease.

In the United States for example, 900,000 people are hospitalized for myocardial infarction every year, and 600,000 succumb to coronary heart disease. Moreover, an increasing proportion of the world's population is reaching an age when coronary heart disease is frequent.
Although medical science is advancing there are increasing numbers of people suffering from cardiovascular diseases. Cardiovascular mortality (data not corrected for age) will therefore continue to rise, making effective and innovative products more essential than ever before.

Treatment of hypertension, congestive heart failure after myocardial infarction

Tritace® is an angiotensin converting enzyme (ACE) inhibitor for the management of hypertension, congestive heart failure after a myocardial infarction.

Due to the results of the HOPE study, it is the only ACE inhibitor so far approved for the prevention of stroke, myocardial infarction and cardiovascular-related death in high-risk patients and diabetics.

Updated April 01, 2006

Module :